Latest News
A team of leading Australian and New Zealand health researchers is undertaking a study to pilot a positive lifestyle intervention in New Zealand women. This aims to improve health and wellness in younger women after treatment for cancer.
The Sweet Louise Cookbook 2020
The Sweet Louise Cookbook 2020 edition is here! Featuring 40 recipes including sweet and savoury concoctions from Nadia Lim, Jacinda Ardern, Al Brown, Hannah Barrett, Kura Forrester, as well as members of the Sweet Louise community, The Sweet Louise Cookbook has something for everybody – no matter what cooking ability!
Busting With Life welcomes breast cancer survivors from across the Auckland region. There are no age restrictions and you do not need to have any previous experience with dragon boating or any other sport. For 22 years and counting, Busting With Life Dragon Boat Team has participated in dragon boat racing to make a difference, to raise awareness of breast cancer and to encourage those living with it to lead full and active lives.
Due to the Government’s movement of COVID-19 alert levels, Look Good Feel Better has postponed in-person community classes. The safety of their participants, volunteers, facilitators, and venue staff is their top priority. For this reason, all community classes are postponed until the Government advises that we are back at Level 1.
Article supplied by PINC and STEEL Cancer Rehabilitation.
More than 3000 people receive a breast cancer diagnosis every year in NZ and too many know that successfully completing treatment is just the beginning of an arduous journey back to health.
Most of us are familiar with Herceptin – the medicine that transformed the treatment of HER2-positive breast cancer in the early 2000s. Herceptin is the brand name for this drug which is supplied by pharmaceutical company Roche. Trastuzumab is its generic name.
Roche’s patents on Herceptin/trastuzumab expired in Europe in 2014 and in the United States in 2019. Now a number of copies of this medicine – called trastuzumab biosimilars – have been developed by other companies and are on the market. With several competing products available, their prices are highly likely to be lower than for the original drug.
The Advanced Breast Cancer Global Alliance, of which BCAC is a member, has joined with other international cancer groups to call for a global plan of action for cancer to meet the challenges of COVID-19 and future pandemics or health crises (see link).
As international research continues to unravel the complexity of breast cancer and its many sub-types, a steady stream of exciting new medicines targeting each type comes to market. Some countries adopt and publicly fund these quickly, but New Zealand does not. Government spending on medicines per capita is lower in New Zealand than in most OECD countries and access to new medicines has been low and slow.
Although campaigns by BCAC and other New Zealand breast cancer patient groups have resulted in funding for a few new breast cancer medicines, such as trastuzumab emtansine (Kadcyla®), palbociclib (Ibrance®) and fulvestrant (Faslodex®), there are still many that are not funded here. Some are available privately if a patient is able to pay for them.
Breast surgeon Dr Eva Juhasz has recently finished a study of the current treatment of elderly breast cancer patients in Waitematā DHB.
A new research project here in New Zealand aims to explore how women with mastectomies and breast reconstructive surgery experience their bodies, particularly focusing on the roles that bras, breasts and body image play in their lives after surgery.
